WebMD Health News
Louise Chang, MD
Dec. 17, 2007 -- Vitamin D compounds, routinely given to patients with
chronic kidney disease to help preserve their bones, are not proven
scientifically to help, according to a new report.
Researchers evaluated 76 published trials on vitamin D compounds, performing
what is known as a meta-analysis, in which the results of several studies are
Bottom line: "Despite many years of use, this is an intervention ... of
unproven efficacy when it comes to achieving what really matters -- that is, a
reduction in deaths, fractures, and cardiovascular events," says Giovanni
Strippoli, MD, research coordinator at the Mario Negri Sud Consortium in Italy
and a co-author of the study.
In chronic kidney disease, caused by such conditions as high blood pressure and
diabetes, the organs do not work properly and can eventually fail, leading
to a need for dialysis.
Chronic kidney disease patients are often deficient in vitamin D, which
helps maintain normal blood levels of calcium and phosphorous and helps promote
calcium absorption, important for strong bones.
Diseased kidneys can't remove excess phosphorous found in foods as normal
kidneys do. As phosphorous builds up, calcium in the blood drops. Then four
small glands in the neck, called the parathyroid glands, become too active and
too much calcium is removed from the bones, causing them to weaken and possibly
fracture, according to the National Kidney Foundation.
When parathyroid hormone, as well as blood levels of phosphorous and
calcium, builds up to excess, the risk of bone fractures, disability, and death
To remedy the problem, doctors generally advise eating a low-phosphorous
diet and taking one of a variety of medicines with a form of vitamin D and
other components, either orally or injectables.
"Vitamin D compounds have been used for over 30 years and are very
widespread," Suetonia Palmer, MBChB, a clinical research training fellow at
the University of Otago, New Zealand, tells WebMD. "However, their effect
on mortality and cardiovascular health remains unknown."
Palmer, Strippoli and their colleagues searched medical databases from
January 1966 through July 2007 to find published studies of vitamin D compounds
for chronic kidney disease. They selected 76 that met their criteria for
inclusion. In all, 3,667 participants were in these 76 studies.
When they pooled the results and analyzed them, the researchers found that
the vitamin D compounds did not consistently reduce the parathyroid hormone
levels or reduce the risk of death, bone pain, blood vessel calcification, or other problems.
When they compared the established vitamin D sterols with placebo, the
vitamin D treatments were associated with a 2.3 times higher risk of high
calcium levels and a nearly two times higher risk of high phosphate in the
blood. And the treatment didn't consistently reduce the parathyroid hormone
Newer types of vitamin D treatment did not perform better.
The analysis is published in the Annals of Internal Medicine.
In an editorial accompanying the analysis, Marcello Tonelli, MD, associate
professor of medicine at the University of Alberta in Edmonton, Canada, writes:
"Palmer and colleagues' findings should serve as yet another warning to the
nephrology community that we do not have good evidence to defend many of our
"We need to do more research," Tonelli tells WebMD. "To figure
out the best role for these medicines, a large trial or trials are needed,
probably funded by a U.S. government agency such as the National Institutes of
He reports as a potential conflict of interest that he receives funding from
the Centre for D-Receptor Activation Research to examine vitamin D status in
remote-dwelling patients on dialysis.
Strippoli and Palmer, too, call for more research in the area to prove the
Meanwhile, those with chronic kidney disease should follow their doctors'
advice, Strippoli says. Until more is known, patients should closely follow, in
particular, advice about preventive measures suggested by their doctors,
including dietary advice and recommendations to undergo longer dialysis
SOURCES: Giovanni Strippoli, MD, MPH, research coordinator, Mario Negri Sud
Consortium, Italy; editor, Cochrane Renal Group. Suetonia Palmer, MBChB, HRC
clinical research training fellow, University of Otago, New Zealand. Palmer, S.
and Tonelli, M. Annals of Internal Medicine, Dec. 18, 2007, vol 147: pp
840-853, 880-881. Marcello Tonelli, MD, University of Alberta and
Institute of Health Economics, Edmonton, Canada.
Here are the most recent story comments.View All
© 2015 Ramar Communications |
Site Map |
Privacy Statement |
Copyright & Trademark Notice |
EEO Report |
FCC Public Files |
Closed Captioning |